Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-09-22
167500.00 KRW   -0.89%
09/22Celltrion, Abpro Partner to Develop, Commercialize Breast Cancer Treatment Drug
MT
09/19Britain’s MHRA Clears Celltrion's Cancer Drug Vegzelma for Marketing in the UK
MT
09/06PTAB Institutes IPRs Of Tocilzumab Patents Challenged By Celltrion
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about CELLTRION, INC.
09/22Celltrion, Abpro Partner to Develop, Commercialize Breast Cancer Treatment Drug
MT
09/19Britain’s MHRA Clears Celltrion's Cancer Drug Vegzelma for Marketing in the UK
MT
08/16Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
CI
08/15Infliximab Clinical Trial Updates
AQ
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/07Celltrion's Net Income Jumps 41.2% in June Quarter
MT
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/26Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 18, 2022.
CI
07/22Celltrion, Inc.'s Equity Buyback announced on May 18, 2022, has closed with 500,000 sha..
CI
06/26Celltrion Wins Sales Approval Recommendation For Its CT-P16 From European Medicines Age..
RE
06/06Celltrion Eyes to Boost Market Share in Europe of Rheumatoid Arthritis Medication to 50..
MT
05/18Celltrion, Inc. authorizes a Buyback Plan.
CI
05/17Celltrion, Inc. announces an Equity Buyback for 500,000 shares.
CI
05/16Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
More most relevant news
All news about CELLTRION, INC.
09/22Celltrion, Abpro Partner to Develop, Commercialize Breast Cancer Treatment Drug
MT
09/19Britain’s MHRA Clears Celltrion's Cancer Drug Vegzelma for Marketing in the UK
MT
09/06PTAB Institutes IPRs Of Tocilzumab Patents Challenged By Celltrion
AQ
09/05S.Korean shares end at over six-week low on Europe energy worries
RE
08/16Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
CI
08/15Infliximab Clinical Trial Updates
AQ
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/07Celltrion's Net Income Jumps 41.2% in June Quarter
MT
08/05S.Korean shares post third straight weekly gain
RE
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
More news
News in other languages on CELLTRION, INC.
08/16Celltrion, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le..
08/07Le revenu net de Celltrion fait un bond de 41,2 % au trimestre de juin
05/25MÄRKTE ASIEN/Breite Erholung - Tokio mit Konjunktursorgen etwas leichter
05/25MÄRKTE ASIEN/Freundlich - Gelegenheitskäufe nach jüngstem Rücksetzer
05/18Celltrion, Inc. autorise un plan de rachat.
05/17CELLTRION, INC. (KOSE : A068270) annonce un rachat d'actions pour 500 000 actions.
05/16Celltrion, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/12Le bénéfice net de Celltrion chute de 39,2 % au premier trimestre ; les actions baissen..
04/27MÄRKTE ASIEN/Tokio und Seoul schwach - Erholungsrally in Schanghai
04/27MÄRKTE ASIEN/Uneinheitlich - Chinesische Börsen knapp im Plus
More news
Press releases
09/06PTAB Institutes IPRs Of Tocilzumab Patents Challenged By Celltrion
AQ
08/15Infliximab Clinical Trial Updates
AQ
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/05CELLTRION : 2Q 2022 Earnings Release_Celltrion Inc.
PU
07/19Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle Eas..
AQ
More press releases
Upcoming event on CELLTRION, INC.